AIM: To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL). METHODS: A multicenter, randomized, double-blind, placebo-controlled intervention clinical trial with three parallel arms was designed. A total of 84 patients (53 female, 31 male; age range 20-70 years) with IBS and diarrhea according to Rome-III criteria were randomly allocated to receive one capsule a day for 6 wk containing: (1) I.31 high dose (n = 28); (2) I.31 low dose (n = 27); and (3) placebo (n = 29). At baseline, and 3 and 6 wk of treatment, patients filled the IBSQoL, Visceral Sensitivity Index (VSI), and global symptom relief questionnaires. RESULTS: During treatment, IBS-QoL increased in all groups, but this increment was significantly larger in patients treated with I.31 than in those receiving placebo (P = 0.008). After 6 wk of treatment, IBS-QoL increased by 18 ± 3 and 22 ± 4 points in the high and the low dose groups, respectively (P = 0.041 and P = 0.023 vs placebo), but only 9 ± 3 in the placebo group. Gut-specific anxiety, as measured with VSI, also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics (by 10 ± 2 and 14 ± 2 points, high and low dose respectively, P < 0.05 for both vs 7 ± 1 score increment in placebo). Symptom relief showed no significant changes between groups. No adverse drug reactions were reported following the consumption of probiotic or placebo capsules. CONCLUSION: A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea.
RCT Entities:
AIM: To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL). METHODS: A multicenter, randomized, double-blind, placebo-controlled intervention clinical trial with three parallel arms was designed. A total of 84 patients (53 female, 31 male; age range 20-70 years) with IBS and diarrhea according to Rome-III criteria were randomly allocated to receive one capsule a day for 6 wk containing: (1) I.31 high dose (n = 28); (2) I.31 low dose (n = 27); and (3) placebo (n = 29). At baseline, and 3 and 6 wk of treatment, patients filled the IBSQoL, Visceral Sensitivity Index (VSI), and global symptom relief questionnaires. RESULTS: During treatment, IBS-QoL increased in all groups, but this increment was significantly larger in patients treated with I.31 than in those receiving placebo (P = 0.008). After 6 wk of treatment, IBS-QoL increased by 18 ± 3 and 22 ± 4 points in the high and the low dose groups, respectively (P = 0.041 and P = 0.023 vs placebo), but only 9 ± 3 in the placebo group. Gut-specific anxiety, as measured with VSI, also showed a significantly greater improvement after 6 wk of treatment in patients treated with probiotics (by 10 ± 2 and 14 ± 2 points, high and low dose respectively, P < 0.05 for both vs 7 ± 1 score increment in placebo). Symptom relief showed no significant changes between groups. No adverse drug reactions were reported following the consumption of probiotic or placebo capsules. CONCLUSION: A new combination of three different probiotic bacteria was superior to placebo in improving IBS-related quality of life in patients with IBS and diarrhea.
Authors: P Jerndal; G Ringström; P Agerforz; M Karpefors; L M Akkermans; A Bayati; M Simrén Journal: Neurogastroenterol Motil Date: 2010-03-25 Impact factor: 3.598
Authors: Douglas A Drossman; L Chang; N Bellamy; H E Gallo-Torres; A Lembo; F Mearin; N J Norton; P Whorwell Journal: Am J Gastroenterol Date: 2011-07-12 Impact factor: 10.864
Authors: Margaret D Eugenio; Sang-Eun Jun; Kevin C Cain; Monica E Jarrett; Margaret M Heitkemper Journal: Dig Dis Sci Date: 2012-06 Impact factor: 3.199
Authors: Mirjana Rajilić-Stojanović; Elena Biagi; Hans G H J Heilig; Kajsa Kajander; Riina A Kekkonen; Sebastian Tims; Willem M de Vos Journal: Gastroenterology Date: 2011-08-05 Impact factor: 22.682
Authors: Premysl Bercik; Emmanuel Denou; Josh Collins; Wendy Jackson; Jun Lu; Jennifer Jury; Yikang Deng; Patricia Blennerhassett; Joseph Macri; Kathy D McCoy; Elena F Verdu; Stephen M Collins Journal: Gastroenterology Date: 2011-04-30 Impact factor: 22.682
Authors: Javier A Bravo; Paul Forsythe; Marianne V Chew; Emily Escaravage; Hélène M Savignac; Timothy G Dinan; John Bienenstock; John F Cryan Journal: Proc Natl Acad Sci U S A Date: 2011-08-29 Impact factor: 11.205
Authors: Magnus Simrén; Giovanni Barbara; Harry J Flint; Brennan M R Spiegel; Robin C Spiller; Stephen Vanner; Elena F Verdu; Peter J Whorwell; Erwin G Zoetendal Journal: Gut Date: 2012-06-22 Impact factor: 23.059
Authors: Piero Portincasa; Giuseppe Celano; Nadia Serale; Paola Vitellio; Francesco Maria Calabrese; Alexandra Chira; Liliana David; Dan L Dumitrascu; Maria De Angelis Journal: Nutrients Date: 2022-06-15 Impact factor: 6.706